202 related articles for article (PubMed ID: 14567030)
21. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Cotte E; Passot G; Tod M; Bakrin N; Gilly FN; Steghens A; Mohamed F; Glehen O
Ann Surg Oncol; 2011 Sep; 18(9):2599-603. PubMed ID: 21424369
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration.
Sugarbaker PH; Stuart OA; Vidal-Jove J; Pessagno AM; DeBruijn EA
Cancer Treat Res; 1996; 82():41-52. PubMed ID: 8849942
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Sugarbaker PH
Dis Colon Rectum; 1994 Feb; 37(2 Suppl):S115-22. PubMed ID: 8313782
[TBL] [Abstract][Full Text] [Related]
24. The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis.
Francescutti V; Rivera L; Seshadri M; Kim M; Haslinger M; Camoriano M; Attwood K; Kane JM; Skitzki JJ
Oncol Rep; 2013 Jul; 30(1):35-42. PubMed ID: 23673557
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics and prophylactic effect of intraperitoneal administration of mitomycin C resulting in IC50 of gastric cancer].
Hiratsuka M; Furukawa H; Iwanaga T; Nagano H; Yasuda T; Masutani S; Oohigashi H; Kameyama M; Sasaki Y; Kabuto T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1541-5. PubMed ID: 2117888
[TBL] [Abstract][Full Text] [Related]
27. [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].
Zoetmulder FA; van der Vange N; Witkamp AJ; Kaag MM; Boot H; Beijnen JH
Ned Tijdschr Geneeskd; 1999 Sep; 143(37):1863-8. PubMed ID: 10526600
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
Wadler S; Egorin MJ; Zuhowski EG; Tortorello L; Salva K; Runowicz CD; Wiernik PH
J Clin Oncol; 1989 Jan; 7(1):132-9. PubMed ID: 2491884
[TBL] [Abstract][Full Text] [Related]
29. [Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Yamauchi M; Ito A; Kodera Y; Kondo K; Nakahara H; Nagai S; Kuzuya T; Satta T; Ito K; Takagi H
Gan To Kagaku Ryoho; 1992 Apr; 19(4):463-8. PubMed ID: 1558395
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Cho HK; Lush RM; Bartlett DL; Alexander HR; Wu PC; Libutti SK; Lee KB; Venzon DJ; Bauer KS; Reed E; Figg WD
J Clin Pharmacol; 1999 Apr; 39(4):394-401. PubMed ID: 10197298
[TBL] [Abstract][Full Text] [Related]
31. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetic study of intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles].
Liang H; Tang HW; Hao XS; Sun H; Li W
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):412-5. PubMed ID: 16188126
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model.
Park EJ; Ahn J; Gwak SW; Park KS; Baik SH; Hwang SJ
Ann Surg Oncol; 2018 Oct; 25(11):3185-3192. PubMed ID: 30027459
[TBL] [Abstract][Full Text] [Related]
34. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
[TBL] [Abstract][Full Text] [Related]
36. [Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles].
Sakakibara T; Oyama T; Ozaki K; Sasaki S; Tsujimoto H; Sakakura C; Shimotsuma M; Hagiwara A; Takahashi T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1700-2. PubMed ID: 8373253
[TBL] [Abstract][Full Text] [Related]
37. A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
Pelz JO; Doerfer J; Hohenberger W; Meyer T
BMC Cancer; 2005 May; 5():56. PubMed ID: 15924622
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.
Kuzuya T; Yamauchi M; Ito A; Hasegawa M; Hasegawa T; Nabeshima T
J Pharm Pharmacol; 1994 Aug; 46(8):685-9. PubMed ID: 7815285
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
